bluebird bio (BLUE) Status Update summary

Restructuring and Cost Management

• Announced a restructuring to reduce cash operating expenses by 20% by Q3 2025, including a 25% workforce reduction, mainly impacting G&A and R&D functions.

• The restructuring aims to optimize cost structure, attract additional capital, and unlock commercial opportunities.

• Focus will intensify on commercial launches of three FDA-approved gene therapies: LYFGENIA, ZYNTEGLO, and SKYSONA.

• The company is targeting cash flow breakeven in the second half of 2025, assuming projected patient starts and additional cash resources are secured.

• Current cash runway extends into Q2 2025, or Q1 2025 considering covenant requirements, with options being evaluated to bridge the gap.

Commercial Performance and Patient Starts

• Accelerated commercial launches across a broad QTC network, with approximately 85 patient starts expected in 2024 and about 40 patient starts anticipated in Q4 2024.

• Year-to-date, 41 patient starts have been recorded, up from 27 in mid-August.

• Q3 2024 projected to reach around 40 patient starts, including over 20 LYFGENIA starts across 31 unique QTCs.

• Patient start process is highly efficient, with most who initiate converting to revenue.

• Once a patient is scheduled for treatment, follow-through rates are high, though timing may shift due to patient health events.

Manufacturing Capacity and Product Mix

• Manufacturing capacity is scaled in line with demand, not in advance, to control costs.

• Capacity is sufficient to reach cash flow breakeven, with plans to double LYFGENIA capacity in 2026 as demand grows.

• Skysona is expected to start 5–10 patients annually, Zynteglo is projected for strong linear growth, and Lyfgenia is anticipated to become the largest product due to a larger eligible patient population.